Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for livedo reticularis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- What evidence exists?
- Tier C (investigational). Only anecdotal use; there are no randomized controlled trials. Most livedo cases are physiologic (cold-related, benign cutis marmorata) and require no therapy beyond warmth and reassurance. Secondary livedo reticularis (associated with antiphospholipid syndrome, systemic lupus erythematosus, vasculitis, polyarteritis nodosa, cholesterol emboli, thrombophilia, or drug exposure) requires identification and treatment of the underlying condition by rheumatology or appropriate specialty. Leech therapy is contraindicated in active inflammatory or thrombotic disease.
- Main risks
- Missed diagnosis of a serious underlying condition (APS, lupus, vasculitis, PAN) if leech therapy is pursued instead of full workup
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over affected limbs for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Worsening of underlying inflammatory or thrombotic disease
- Permanent visible scars at bite sites
- Who should not consider this
- Patients with secondary livedo from an untreated underlying condition
- Patients with antiphospholipid syndrome with thrombosis history
- Patients on anticoagulants for APS, thrombophilia, or recurrent thrombosis
- Patients with active vasculitis, polyarteritis nodosa, or systemic lupus
- Patients with critical limb ischemia or recent cholesterol embolism
- Patients who have not had a rheumatologic and hematologic workup
- What to ask your clinician
- Has the livedo been classified as primary (benign physiologic) or secondary?
- Have I been screened for antiphospholipid antibodies, ANA, complement, and a hypercoagulable workup?
- Are there other systemic symptoms (joint pain, fatigue, rashes, organ involvement) suggesting an autoimmune cause?
- Has a skin biopsy been considered if vasculitis or cholesterol emboli are possible?
- What is my management plan if a secondary cause is found?
- What evidence supports leech therapy for livedo specifically?
- What is the practitioner's experience and Aeromonas-prevention plan?
- When to seek urgent care
- Sudden severe leg pain, coldness, pallor, or pulselessness (acute limb ischemia — call 911)
- New unilateral leg swelling, redness, and pain (possible DVT)
- New stroke-like symptoms (weakness, slurred speech, vision change) — could indicate APS
- Recurrent pregnancy loss (APS workup needed)
- Painful skin ulcers within livedo areas (livedoid vasculopathy or vasculitis)
- Fever, joint pain, kidney symptoms, or new rash (autoimmune flare)
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for livedo reticularis.
- Anecdotal use does NOT establish efficacy or rule out underlying systemic disease.
- Mechanism rationale (rheologic effects) does NOT replace the workup of secondary causes.
- Leech therapy is NOT a substitute for rheumatology and hematology evaluation.
- Secondary livedo from APS, lupus, vasculitis, or thrombophilia requires treatment of the underlying disease, NOT complementary therapy.
Safety cross-references
Clinical Profile
- Category
- dermatological
- ICD-10
- R23.1, I73.89
- Safety tier
- high
Evidence Summary
Anecdotal use only; no controlled trial or case series of sufficient quality exists to assess any effect size, so use is investigational and mechanistic only. The proposed mechanism is local rheologic improvement from absorbed hirudin and salivary fibrinolytic enzymes. Secondary livedo (associated with antiphospholipid syndrome, vasculitis, or polyarteritis nodosa) requires identification and treatment of the underlying condition, and leech therapy is contraindicated until the inflammatory process is controlled. Primary livedo (cold-related, idiopathic) may be considered for symptomatic intervention only on an exploratory basis. Current ASH position: exploratory use only.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Ahmed M et al. (2021), n=6
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Secondary livedo with untreated underlying condition
- Active antiphospholipid syndrome with thrombosis
Related ASH Compounds
Leech-derived molecules implicated in this condition, each profiled in the ASH compound registry:
Related Conditions
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.
Rosacea (Erythematotelangiectatic)
Investigational use for erythematotelangiectatic rosacea; case-series evidence for reduction in facial erythema.